HRP20170810T1 - Peptidi i spojevi koji se vežu za receptore trombopoietina - Google Patents
Peptidi i spojevi koji se vežu za receptore trombopoietina Download PDFInfo
- Publication number
- HRP20170810T1 HRP20170810T1 HRP20170810TT HRP20170810T HRP20170810T1 HR P20170810 T1 HRP20170810 T1 HR P20170810T1 HR P20170810T T HRP20170810T T HR P20170810TT HR P20170810 T HRP20170810 T HR P20170810T HR P20170810 T1 HRP20170810 T1 HR P20170810T1
- Authority
- HR
- Croatia
- Prior art keywords
- compound
- cells
- use according
- sarcosine
- nal
- Prior art date
Links
- 150000001875 compounds Chemical class 0.000 title claims 41
- 102000005763 Thrombopoietin Receptors Human genes 0.000 title claims 8
- 108010070774 Thrombopoietin Receptors Proteins 0.000 title claims 8
- 108090000765 processed proteins & peptides Proteins 0.000 title claims 5
- 102000004196 processed proteins & peptides Human genes 0.000 title claims 5
- FSYKKLYZXJSNPZ-UHFFFAOYSA-N sarcosine Chemical compound C[NH2+]CC([O-])=O FSYKKLYZXJSNPZ-UHFFFAOYSA-N 0.000 claims 16
- 210000004027 cell Anatomy 0.000 claims 11
- 108010077895 Sarcosine Proteins 0.000 claims 8
- UCMIRNVEIXFBKS-UHFFFAOYSA-N beta-alanine Chemical compound NCCC(O)=O UCMIRNVEIXFBKS-UHFFFAOYSA-N 0.000 claims 8
- 229940043230 sarcosine Drugs 0.000 claims 8
- 229920001477 hydrophilic polymer Polymers 0.000 claims 7
- 206010043554 thrombocytopenia Diseases 0.000 claims 7
- 229920000642 polymer Polymers 0.000 claims 6
- 238000002512 chemotherapy Methods 0.000 claims 5
- 238000001959 radiotherapy Methods 0.000 claims 5
- 238000011282 treatment Methods 0.000 claims 5
- 239000002202 Polyethylene glycol Substances 0.000 claims 4
- 229940000635 beta-alanine Drugs 0.000 claims 4
- 229920001223 polyethylene glycol Polymers 0.000 claims 4
- 229920001184 polypeptide Polymers 0.000 claims 4
- JPZXHKDZASGCLU-LBPRGKRZSA-N β-(2-naphthyl)-alanine Chemical compound C1=CC=CC2=CC(C[C@H](N)C(O)=O)=CC=C21 JPZXHKDZASGCLU-LBPRGKRZSA-N 0.000 claims 4
- 210000003593 megakaryocyte Anatomy 0.000 claims 3
- 125000003545 alkoxy group Chemical group 0.000 claims 2
- 125000000217 alkyl group Chemical group 0.000 claims 2
- 239000003937 drug carrier Substances 0.000 claims 2
- 230000002163 immunogen Effects 0.000 claims 2
- 239000000203 mixture Substances 0.000 claims 2
- 229920001451 polypropylene glycol Polymers 0.000 claims 2
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 claims 2
- 102100031573 Hematopoietic progenitor cell antigen CD34 Human genes 0.000 claims 1
- 101000777663 Homo sapiens Hematopoietic progenitor cell antigen CD34 Proteins 0.000 claims 1
- 229920000954 Polyglycolide Polymers 0.000 claims 1
- 229940123936 Thrombopoietin agonist Drugs 0.000 claims 1
- 239000002253 acid Substances 0.000 claims 1
- 230000003213 activating effect Effects 0.000 claims 1
- 239000005557 antagonist Substances 0.000 claims 1
- 210000001185 bone marrow Anatomy 0.000 claims 1
- 238000010322 bone marrow transplantation Methods 0.000 claims 1
- 125000004432 carbon atom Chemical group C* 0.000 claims 1
- 230000001419 dependent effect Effects 0.000 claims 1
- 239000000539 dimer Substances 0.000 claims 1
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 claims 1
- 238000000034 method Methods 0.000 claims 1
- 239000000825 pharmaceutical preparation Substances 0.000 claims 1
- 239000004633 polyglycolic acid Substances 0.000 claims 1
- 239000002243 precursor Substances 0.000 claims 1
- 238000011321 prophylaxis Methods 0.000 claims 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- C07K14/52—Cytokines; Lymphokines; Interferons
- C07K14/524—Thrombopoietin, i.e. C-MPL ligand
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
- A61K38/03—Peptides having up to 20 amino acids in an undefined or only partially defined sequence; Derivatives thereof
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
- A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
- A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
- A61K47/56—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic macromolecular compound, e.g. an oligomeric, polymeric or dendrimeric molecule
- A61K47/59—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic macromolecular compound, e.g. an oligomeric, polymeric or dendrimeric molecule obtained otherwise than by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyureas or polyurethanes
- A61K47/60—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic macromolecular compound, e.g. an oligomeric, polymeric or dendrimeric molecule obtained otherwise than by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyureas or polyurethanes the organic macromolecular compound being a polyoxyalkylene oligomer, polymer or dendrimer, e.g. PEG, PPG, PEO or polyglycerol
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P7/00—Drugs for disorders of the blood or the extracellular fluid
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P7/00—Drugs for disorders of the blood or the extracellular fluid
- A61P7/02—Antithrombotic agents; Anticoagulants; Platelet aggregation inhibitors
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P7/00—Drugs for disorders of the blood or the extracellular fluid
- A61P7/04—Antihaemorrhagics; Procoagulants; Haemostatic agents; Antifibrinolytic agents
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K7/00—Peptides having 5 to 20 amino acids in a fully defined sequence; Derivatives thereof
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K7/00—Peptides having 5 to 20 amino acids in a fully defined sequence; Derivatives thereof
- C07K7/04—Linear peptides containing only normal peptide links
- C07K7/08—Linear peptides containing only normal peptide links having 12 to 20 amino acids
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- General Health & Medical Sciences (AREA)
- Medicinal Chemistry (AREA)
- Organic Chemistry (AREA)
- Pharmacology & Pharmacy (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Animal Behavior & Ethology (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Engineering & Computer Science (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Epidemiology (AREA)
- Biochemistry (AREA)
- Biophysics (AREA)
- Molecular Biology (AREA)
- Genetics & Genomics (AREA)
- Zoology (AREA)
- Gastroenterology & Hepatology (AREA)
- General Chemical & Material Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Immunology (AREA)
- Hematology (AREA)
- Toxicology (AREA)
- Diabetes (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Peptides Or Proteins (AREA)
- Medicinal Preparation (AREA)
- Polyethers (AREA)
Claims (31)
1. Spoj koji se veže za receptor trombopoietina (TPO), naznačen time da navedeni spoj sadrži (H-IEGPTLRQ(2-Nal)LAARX10)2K-NH2, pri čemu je X10 odabran iz skupine koju čine sarkozin ili β-alanin, gdje je 2-Nal β-(2-naftil)alanin, te pri čemu je navedeni spoj kovalentno vezan za hidrofilni polimer.
2. Spoj prema zahtjevu 1, naznačen time da X10 je sarkozin.
3. Spoj prema zahtjevu 1 ili zahtjevu 2, naznačen time da navedeni hidrofilni polimer ima srednju molekulsku masu između oko 500 do oko 40000 Daltona.
4. Spoj prema zahtjevu 1 ili zahtjevu 2, naznačen time da navedeni hidrofilni polimer ima srednju molekulsku masu između oko 5000 do oko 20000 Daltona.
5. Spoj prema zahtjevu 1 ili zahtjevu 2, naznačen time da je navedeni polimer odabran iz skupine koju čine polietilen glikol, polipropilen glikol, poliloctena kiselina i poliglikolna kiselina.
6. Spoj prema zahtjevu 5, naznačen time da je navedeni spoj kovalentno vezan za polietilen glikol.
7. Spoj prema zahtjevu 1 ili zahtjevu 2, naznačen time da je svaka dimerna podjedinica navedenog spoja vezana za hidrofilni polimer.
8. Farmaceutski pripravak naznačen time da sadrži spoj prema zahtjevu 1 ili zahtjevu 2 u kombinaciji s farmaceutski prihvatljivim nosačem.
9. Spoj prema zahtjevu 1 ili zahtjevu 2 za upotrebu u liječenju pacijenta koji pati od poremećaja koji je osjetljiv na tretman sa agonistom trombopoietina, koje obuhvaća davanje pacijentu terapeutski učinkovite doze ili količine spoja prema zahtjevu 1.
10. Fiziološki aktivan, uglavnom neimunogeni polipeptidni pripravak otopljen u vodi koji sadrži spoj prema zahtjevu 1 ili zahtjevu 2, naznačen time da je navedeni polimer odabran iz skupine koju čine polietilen glikol i polipropilen glikol, i pri čemu je navedeni polimer nesupstituiran ili supstituiran s alkoksi ili alkil skupinama, a navedene alkoksi ili alkil skupine sadrže manje od 5 ugljikovih atoma.
11. Polipeptidni pripravak prema zahtjevu 10, naznačen time da navedeni polimer ima molekulsku masu od oko 750 do oko 15000 Daltona.
12. Polipeptidni pripravak prema zahtjevu 10, naznačen time da navedeni polimer ima molekulsku masu od oko 5 000 do oko 10000 Daltona.
13. Polipeptidni pripravak prema zahtjevu 11, naznačen time da je navedeni polimer polietilen glikol.
14. Uglavnom neimunogeni pripravak otopljen u vodi naznačen time da sadrži pripravak prema zahtjevu 10 i farmaceutski prihvatljiv nosač.
15. Spoj za uporabu u aktiviranju receptora trombopoietina (TPO) u stanici, naznačen time da navedeni spoj sadrži (HIEGPTLRQ(2-Nal)LAARX10)2K-NH2, pri čemu je X10 odabran iz skupine koju čine sarkozin ili β-alanin, pri čemu 2-Nal je β-(2-naftil)alanin, i pri čemu je navedeni spoj kovalentno vezan za hidrofilni polimer.
16. Spoj za uporabu prema zahtjevu 15, naznačen time da X10 je sarkozin.
17. Spoj za uporabu prema zahtjevu 15 ili 16 naznačen time da navedene stanice sadrže ljudske megakariocite, trombocite ili CD34+ stanice.
18. Spoj za uporabu prema zahtjevu 15 ili 16 naznačen time da navedene stanice sadrže TPO-ovisne stanice.
19. Spoj prema zahtjevu 1 ili 2 za upotrebu u postupku liječenja trombocitopenije kod subjekta, naznačen time da postupak sadrži:
(a) dobivanje populacije stanica iz subjekta koje sadrže prekursore stanica megakariocita;
(b) dovođenje u kontakt navedenih stanica sa spojem da se da bi se aktivirali receptori trombopoietina u stanicama; i
(c) davanje navedenih stanica koje su bile u kontaktu s navedenim subjektom, da bi se povećao broj megakariocita prisutnih u navedenom subjektu u usporedbi s onim koji bi se javio bez ovog tretmana.
20. Spoj za uporabu prema zahtjevu 19, naznačen time da je navedena trombocitopenija posljedica kemoterapije.
21. Spoj za uporabu prema zahtjevu 20, naznačen time da je navedena populacija stanica dobivena prije navedene kemoterapije.
22. Spoj za uporabu prema zahtjevu 19, naznačen time da je navedena trombocitopenija posljedica terapije zračenjem.
23. Spoj za uporabu prema zahtjevu 22, naznačen time da je navedena populacija stanica dobivena prije navedene terapije zračenjem.
24. Spoj za uporabu u liječenju pacijenta koji pati od trombocitopenije, koji sadrži davanje navedenom pacijentu terapeutski učinkovite doze spoja koji sadrži (H-IEGPTLRQ(2-Nal)LAARX10)2K-NH2, naznačen time da je X10 odabran iz skupine koju čine sarkozin ili β-alanin, pri čemu 2-Nal je β-(2-naftil)alanin, i pri čemu je navedeni spoj kovalentno vezan za hidrofilni polimer.
25. Spoj za uporabu prema zahtjevu 24, naznačen time da X10 je sarkozin.
26. Spoj za uporabu prema zahtjevu 24 ili 25 naznačen time da je navedena trombocitopenija posljedica kemoterapije ili terapije zračenjem.
27. Spoj za uporabu prema zahtjevu 24 ili 25 naznačen time da se antagonist TPO daje navedenom pacijentu prije navedene kemoterapije ili terapije zračenjem.
28. Spoj za uporabu prema zahtjevu 24 ili 25, naznačen time da je navedena trombocitopenija posljedica transfuzije koštane srži.
29. Spoj za uporabu u profilaktičkom tretmanu pacijenta koji je u opasnosti od trombocitopenije, koji obuhvata davanje navedenom pacijentu profilaktički učinkovite količine spoja koji sadrži (H-IEGPTLRQ(2-Nal)LAARX10)2KNH2, pri čemu je X10 odabran iz skupine koju čine sarkozin ili β-alanin, pri čemu 2-Nal je β-(2-naftil) alanin, i pri čemu je navedeni spoj kovalentno vezan za hidrofilni polimer.
30. Spoj za uporabu prema zahtjevu 29, naznačen time da X10 je sarkozin.
31. Spoj za uporabu prema zahtjevu 29 ili 30, naznačen time da se navedeni spoj daje prije transplantacije koštane srži, kemoterapije ili terapije zračenjem.
Applications Claiming Priority (3)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US49874003P | 2003-08-28 | 2003-08-28 | |
EP04781153.4A EP1675606B1 (en) | 2003-08-28 | 2004-08-13 | Peptides and compounds that bind to thrombopoietin receptors |
PCT/US2004/026422 WO2005023834A2 (en) | 2003-08-28 | 2004-08-13 | Peptides and compounds that bind to thrombopoietin receptors |
Publications (1)
Publication Number | Publication Date |
---|---|
HRP20170810T1 true HRP20170810T1 (hr) | 2017-08-11 |
Family
ID=34272720
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
HRP20170810TT HRP20170810T1 (hr) | 2003-08-28 | 2017-05-30 | Peptidi i spojevi koji se vežu za receptore trombopoietina |
Country Status (33)
Country | Link |
---|---|
US (1) | US7576056B2 (hr) |
EP (1) | EP1675606B1 (hr) |
JP (1) | JP4848277B2 (hr) |
KR (2) | KR20120078742A (hr) |
CN (2) | CN102241742B (hr) |
AR (1) | AR045530A1 (hr) |
AU (1) | AU2004270656B2 (hr) |
BR (1) | BRPI0414008B8 (hr) |
CA (1) | CA2537421C (hr) |
CY (1) | CY1118965T1 (hr) |
DK (1) | DK1675606T3 (hr) |
EA (1) | EA009286B1 (hr) |
EC (1) | ECSP066396A (hr) |
ES (1) | ES2626107T3 (hr) |
HK (1) | HK1096873A1 (hr) |
HR (1) | HRP20170810T1 (hr) |
HU (1) | HUE032370T2 (hr) |
IL (1) | IL173965A (hr) |
IS (1) | IS8300A (hr) |
LT (1) | LT1675606T (hr) |
ME (1) | ME00313B (hr) |
MX (1) | MXPA06002292A (hr) |
NO (1) | NO344233B1 (hr) |
NZ (1) | NZ545455A (hr) |
PL (1) | PL1675606T3 (hr) |
PT (1) | PT1675606T (hr) |
RS (2) | RS20060141A (hr) |
SG (1) | SG131110A1 (hr) |
SI (1) | SI1675606T1 (hr) |
TW (1) | TWI348375B (hr) |
UA (1) | UA82710C2 (hr) |
WO (1) | WO2005023834A2 (hr) |
ZA (1) | ZA200602495B (hr) |
Families Citing this family (19)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US7091311B2 (en) * | 1996-06-07 | 2006-08-15 | Smithkline Beecham Corporation | Peptides and compounds that bind to a receptor |
ES2279649T3 (es) | 1998-10-23 | 2007-08-16 | Amgen Inc. | Compuestos trombopoyeticos. |
ES2781475T3 (es) | 2002-09-18 | 2020-09-02 | Janssen Pharmaceuticals Inc | Métodos para aumentar la producción de células madre hematopoyéticas y plaquetas |
US20040149235A1 (en) * | 2002-10-04 | 2004-08-05 | Pogue Albert S. | Apparatus and method for removal of waste from animal production facilities |
US7723295B2 (en) * | 2003-08-28 | 2010-05-25 | Ortho-Mcneil Pharmaceutical, Inc. | Peptides and compounds that bind to a receptor |
SG131110A1 (en) | 2003-08-28 | 2007-04-26 | Ortho Mcneil Pharm Inc | Peptides and compounds that bind to thrombopoietin receptors |
US7615533B2 (en) | 2004-08-16 | 2009-11-10 | Janssen Pharmaceutica N.V. | TPO peptide compounds for treatment of anemia |
US20090053242A1 (en) * | 2006-01-25 | 2009-02-26 | Amgen Inc. | Thrombopoietic compounds |
AU2006338308B2 (en) * | 2006-02-14 | 2012-11-01 | Janssen Pharmaceutica N.V. | Use of TPO peptide compounds and pharmaceutical compositions in the treatment of anemia |
AR059573A1 (es) * | 2006-02-14 | 2008-04-16 | Janssen Pharmaceutica Nv | Uso de compuestos peptidicos de tpo y composiciones farmaceuticas en el tratamiento de la anemia |
US7981425B2 (en) | 2006-06-19 | 2011-07-19 | Amgen Inc. | Thrombopoietic compounds |
WO2009148954A2 (en) * | 2008-06-03 | 2009-12-10 | Janssen Pharmaceutica Nv | Dosing regimen |
CN103635514B (zh) | 2011-06-23 | 2016-01-20 | 株式会社岛津制作所 | 支链型两亲性嵌段聚合物、使用其的分子聚集体及药物输送*** |
AU2018306329A1 (en) * | 2017-07-26 | 2020-02-13 | Janssen Pharmaceutica Nv | Methods of protecting vascular integrity induced by targeted radiation therapy |
WO2020154585A1 (en) | 2019-01-25 | 2020-07-30 | Janssen Pharmaceutica Nv | Methods for mitigating liver injury and promoting liver hypertrophy, regeneration and cell engraftment in conjunction with radiation and/or radiomimetic treatments |
JP2022523295A (ja) | 2019-01-25 | 2022-04-22 | ヤンセン ファーマシューティカ エヌ.ベー. | 発疱剤および苛性ガスの毒性作用を緩和する方法 |
WO2020154637A1 (en) | 2019-01-25 | 2020-07-30 | Janssen Pharmaceutica Nv | Methods of enhancing protection against organ and vascular injury, hematopoietic recovery and survival in response to total body radiation/chemical exposure |
US20230104658A1 (en) | 2021-10-01 | 2023-04-06 | Janssen Pharmaceutica Nv | Methods of increasing progenitor cell production |
WO2024095178A1 (en) | 2022-11-01 | 2024-05-10 | Janssen Pharmaceutica Nv | Thrombopoietin mimetic for use in the treatment of acute liver failure |
Family Cites Families (33)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US5143854A (en) | 1989-06-07 | 1992-09-01 | Affymax Technologies N.V. | Large scale photolithographic solid phase synthesis of polypeptides and receptor binding screening thereof |
US5326558A (en) | 1989-08-08 | 1994-07-05 | Genetics Institute, Inc. | Megakaryocytopoietic factor |
IL96477A0 (en) | 1989-12-01 | 1991-08-16 | Amgen Inc | Megakaryocyte production |
DK167813B1 (da) | 1989-12-07 | 1993-12-20 | Carlbiotech Ltd As | Pentapeptidderivat, farmaceutisk acceptable salte heraf, fremgangsmaade til fremstilling deraf og farmaceutisk praeparat indeholdende et saadant derivat |
US5571508A (en) | 1989-12-18 | 1996-11-05 | Amrad Corporation Limited | Method for the treatment of thrombocytopenia and pharmaceutical compositions useful therefor |
IT1241395B (it) | 1990-04-02 | 1994-01-10 | Eniricerche Spa | Composti immunogenici,il procedimento per la loro sintesi e loro impiego per la preparazione di vaccini antimalaria |
US5141851A (en) | 1990-04-18 | 1992-08-25 | Board Of Regents, The University Of Texas System | Isolated farnesyl protein transferase enzyme |
US5250732A (en) | 1991-07-18 | 1993-10-05 | Genentech, Inc. | Ketamine analogues for treatment of thrombocytopenia |
US5270170A (en) | 1991-10-16 | 1993-12-14 | Affymax Technologies N.V. | Peptide library and screening method |
ATE222500T1 (de) | 1992-06-11 | 2002-09-15 | Alkermes Inc | Enythropoietin enthaltendes arzneimittelabgabesystem |
JP3401005B2 (ja) | 1992-12-11 | 2003-04-28 | ユニバーシティ オブ フロリダ | 有害生物の防除のための材料および方法 |
AU8124694A (en) | 1993-10-29 | 1995-05-22 | Affymax Technologies N.V. | In vitro peptide and antibody display libraries |
SG47030A1 (en) | 1994-01-03 | 1998-03-20 | Genentech Inc | Thrombopoietin |
CA2169173C (en) | 1994-02-14 | 2002-10-15 | Kenneth Kaushansky | Methods for stimulating erythropoiesis using thrombopoietin |
SG79882A1 (en) | 1994-02-14 | 2001-04-17 | Kirin Brewery | Protein having tpo activity |
CA2183266A1 (en) | 1994-02-14 | 1995-08-17 | Richard D. Holly | Hematopoietic protein and materials and methods for making it |
WO1995021919A2 (en) | 1994-02-14 | 1995-08-17 | Kirin Brewery Company, Limited | Protein having tpo activity |
AU691606B2 (en) | 1994-03-31 | 1998-05-21 | Amgen, Inc. | Compositions and methods for stimulating megakaryocyte growth and differentiation |
US5571686A (en) | 1994-04-14 | 1996-11-05 | Massachusetts Institute Of Technology | Method of using megapoietin for prolonging the survival & viability of platlets |
ATE190304T1 (de) * | 1994-11-04 | 2000-03-15 | Santen Pharmaceutical Co Ltd | Neue hydroxy-substituierte 1,3-dialkyl- harnstoffderivate |
US5641655A (en) | 1994-11-30 | 1997-06-24 | Zymogenetics, Inc. | Methods for producing thrombopoietin polypeptides using a mammalian tissue plasminogen activator secretory peptide |
AU4163196A (en) | 1994-11-30 | 1996-06-19 | Zymogenetics Inc. | Low molecular weight thrombopoietin |
DE69636714T2 (de) | 1995-04-26 | 2007-10-18 | Kyowa Hakko Kogyo Co., Ltd. | G-CSF TPO Fusionsproteine |
US6251864B1 (en) * | 1995-06-07 | 2001-06-26 | Glaxo Group Limited | Peptides and compounds that bind to a receptor |
US5869451A (en) * | 1995-06-07 | 1999-02-09 | Glaxo Group Limited | Peptides and compounds that bind to a receptor |
US6083913A (en) * | 1995-06-07 | 2000-07-04 | Glaxo Wellcome Inc. | Peptides and compounds that bind to a thrombopoietin receptor |
US6060052A (en) | 1995-10-30 | 2000-05-09 | Systemix, Inc. | Methods for use of Mpl ligands with primitive human hematopoietic stem cells |
US5932546A (en) | 1996-10-04 | 1999-08-03 | Glaxo Wellcome Inc. | Peptides and compounds that bind to the thrombopoietin receptor |
DE60032783T2 (de) | 1999-09-24 | 2007-12-06 | Smithkline Beecham Corp. | Thrombopoietinmimetika |
EP1343808B1 (en) * | 2000-12-22 | 2006-09-13 | Ipsen Manufacturing Ireland Limited | Process for the synthesis of an lhrh peptide |
WO2002078612A2 (en) | 2001-04-02 | 2002-10-10 | Euro-Celtique S.A. | Thrombopoietin (tpo) synthebody for stimulation of platelet production |
ES2781475T3 (es) * | 2002-09-18 | 2020-09-02 | Janssen Pharmaceuticals Inc | Métodos para aumentar la producción de células madre hematopoyéticas y plaquetas |
SG131110A1 (en) | 2003-08-28 | 2007-04-26 | Ortho Mcneil Pharm Inc | Peptides and compounds that bind to thrombopoietin receptors |
-
2004
- 2004-08-13 SG SG200701488-9A patent/SG131110A1/en unknown
- 2004-08-13 JP JP2006524705A patent/JP4848277B2/ja active Active
- 2004-08-13 MX MXPA06002292A patent/MXPA06002292A/es active IP Right Grant
- 2004-08-13 KR KR1020127014067A patent/KR20120078742A/ko not_active Application Discontinuation
- 2004-08-13 RS YUP-2006/0141A patent/RS20060141A/sr unknown
- 2004-08-13 WO PCT/US2004/026422 patent/WO2005023834A2/en active Application Filing
- 2004-08-13 DK DK04781153.4T patent/DK1675606T3/en active
- 2004-08-13 HU HUE04781153A patent/HUE032370T2/en unknown
- 2004-08-13 EP EP04781153.4A patent/EP1675606B1/en active Active
- 2004-08-13 CN CN201110134196.XA patent/CN102241742B/zh active Active
- 2004-08-13 PT PT47811534T patent/PT1675606T/pt unknown
- 2004-08-13 CA CA2537421A patent/CA2537421C/en active Active
- 2004-08-13 RS YU20060141A patent/RS56387B1/sr unknown
- 2004-08-13 US US10/918,561 patent/US7576056B2/en active Active
- 2004-08-13 UA UAA200602523A patent/UA82710C2/uk unknown
- 2004-08-13 NZ NZ545455A patent/NZ545455A/en unknown
- 2004-08-13 PL PL04781153T patent/PL1675606T3/pl unknown
- 2004-08-13 BR BRPI0414008A patent/BRPI0414008B8/pt active IP Right Grant
- 2004-08-13 EA EA200600477A patent/EA009286B1/ru unknown
- 2004-08-13 CN CN2004800314520A patent/CN1871022B/zh active Active
- 2004-08-13 AU AU2004270656A patent/AU2004270656B2/en active Active
- 2004-08-13 LT LTEP04781153.4T patent/LT1675606T/lt unknown
- 2004-08-13 KR KR1020067003755A patent/KR101183875B1/ko not_active IP Right Cessation
- 2004-08-13 ES ES04781153.4T patent/ES2626107T3/es active Active
- 2004-08-13 ME MEP-2008-485A patent/ME00313B/me unknown
- 2004-08-13 SI SI200432391A patent/SI1675606T1/sl unknown
- 2004-08-27 TW TW093125674A patent/TWI348375B/zh active
- 2004-08-27 AR ARP040103101A patent/AR045530A1/es active IP Right Grant
-
2006
- 2006-02-14 IS IS8300A patent/IS8300A/is unknown
- 2006-02-24 EC EC2006006396A patent/ECSP066396A/es unknown
- 2006-02-27 IL IL173965A patent/IL173965A/en active IP Right Grant
- 2006-03-24 NO NO20061346A patent/NO344233B1/no unknown
- 2006-03-27 ZA ZA200602495A patent/ZA200602495B/en unknown
-
2007
- 2007-04-16 HK HK07103946.2A patent/HK1096873A1/xx not_active IP Right Cessation
-
2017
- 2017-05-30 HR HRP20170810TT patent/HRP20170810T1/hr unknown
- 2017-06-15 CY CY20171100628T patent/CY1118965T1/el unknown
Also Published As
Similar Documents
Publication | Publication Date | Title |
---|---|---|
HRP20170810T1 (hr) | Peptidi i spojevi koji se vežu za receptore trombopoietina | |
EP2726115B1 (en) | Procoagulant peptides and their derivatives and uses therefor | |
RU2503460C2 (ru) | Применение противомикробного полипептида для лечения микробных нарушений | |
ES2842210T3 (es) | 4F-benzoil-TN14003 para la movilización de células progenitoras hematopoyéticas con vistas al trasplante | |
US20060115457A1 (en) | Biocompatible hydrogel compositions | |
US20080152668A1 (en) | Thymosin Alpha 1 Peptide/Polymer Conjugates | |
ES2703826T3 (es) | Inmunoterapia con IL-12 destinada al cáncer | |
BRPI0514297A (pt) | composições farmacêuticas para liberação controlada de compostos biologicamente ativos | |
EP2506852A2 (en) | Interferon therapies in combination with blockade of stat3 activation | |
ATE432689T1 (de) | Arzneimittelformulierungen mit verzögerter freisetzung mit einem trägerpeptid | |
JP2009504650A5 (hr) | ||
WO2012018718A1 (en) | Absorbable peg-based hydrogels | |
US11617778B2 (en) | Ionic self-assembling peptides | |
EP3250251A1 (en) | Joint fat pad formulations, and methods of use thereof | |
JP2007504132A5 (hr) | ||
KR20080099234A (ko) | 콤브레타스타틴 및 항암제를 포함하는 조합물 | |
AU2002353964A1 (en) | Thymosin alpha 1 peptide/polymer conjugates | |
AU2002363248B2 (en) | Method of administering a Thymosin alpha 1 peptide | |
ES2186596T3 (es) | Uso de inhibidores de la interleucina-18 para inhibir metastasis tumorales. | |
ES2607986T3 (es) | Agentes terapéuticos para regular el fósforo en suero | |
AU2009208481B2 (en) | Pharmaceutical composition and combined agent | |
WO2005009333A2 (en) | Combined treatments comprising synthetic peptide copolymers for preventing graft rejection | |
WO2018022457A1 (en) | Accelerated healing by injectable multi-arm branched amphiphilic scaffolds loaded with hydrophobic drugs | |
EP4340890A1 (en) | Osteotropic compositions and uses thereof | |
EA201000507A1 (ru) | Фармацевтическая композиция пролонгированного действия для снижения аппетита |